Physician profile
Joseph Mun
NPI 1588635940
$13,298.62
in general payments reported to CMS, 2019-2025
51 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,549 · 2020: $2,016 · 2021: $2,327 · 2022: $1,534 · 2023: $1,783 · 2024: $1,699 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,778 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,778.32 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,725.10 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,700.79 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,309.43 | 2019-2025 | |
| Lilly USA, LLC | $1,065.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $817.62 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Glaxosmithkline, LLC. | $689.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $666.21 | 2019-2021 | |
| Amgen INC. | $502.89 | 2019-2024 | Repatha, Otezla |
| Allergan, INC. | $433.80 | 2019-2020 | |
| Pfizer INC. | $398.46 | 2019-2025 | |
| Astellas Pharma US INC | $384.06 | 2019-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $294.82 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $285.42 | 2019-2021 | |
| Ibsa Pharma INC. | $248.15 | 2020-2025 | Licart, Tirosint, Tirosint |
| Philips North America LLC | $230.57 | 2019-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.